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Epstein-Barr virus (EBV) transforms the human B­
lymphocytes it infects into lymphoblasts that are com­
petent to proliferate indefinitely in tissue culture [1]. 
The dividing transformed lymphoblasts carry multiple 
and complete copies of EBV DNA as plasmids [1]. No 
viral functions that are necessary for EBV-induced 
transformation have been identified and characterized 
to date. We have developed an assay that aids in the 
identification of viral functions needed to maintain the 
viral plasmid in transformed cells. The assay employs a 
plasmid vector that encodes resistance to ampicillin and 
can replicate in E. coli. It also encodes resistance to the 
neomycin derivative G4l8, so that its presence can be 
selected in mammalian cells [2]. Fragments of viral DNA 
that span the genome have been molecularly cloned into 
this vector. These recombinant molecules have been 
transfected into four cell types, and survivors to G418 
have been scored. The DNA from one region of EBV 
gives a 10- to 100-fold higher rate of survival per mi­
crogram of added DNA than does the DNA from all 
other recombinants, as tested in cells that already con­
tain EBV genomes. This recombinant fragment of EBV 
is maintained in an apparently unrearranged state as a 
plasmid and therefore carries at least those cis-acting 
viral elements necessary for plasmid replication. 
E pstein-Barr virus (E BV) is a human pathogen associated 
with four proliferative diseases [I]. It causes the heterophile­
positive form of infectious mononucleosis, which is a self­
limiting proliferation. It is causally related to three progres­
sively proliferating diseases: Burkitt's lymphoma, nasopha­
ryngeal carcinoma, and an immunoblastic neoplasm found only 
in severely immunocompromised hosts. The role EBV plays in 
these diseases has not been defined. In all cases, however, at 
least some of the cells infected by the virus are competent to 
proliferate. It may be that EBV's contribution to these diseases 
is its induction and maintenance of division in the infected cell 
[3]. 
In vitro EBV infects human B-lymphocytes and induces the 
infected cell to become a blast and to proliferate. The infected 
cell is said to be transformed or immortalized ber:ause it prolif­
erates and does not go through the crisis and cell death asso­
ciated with human fibroblast cultures. Transformation of hu­
man B-Iymphocytes by EBV in vitro is studied both to under­
stand this process and with the hope that in so doing E BV's 
contributions to diseases will be better defined. Consideration 
of some lymphoid diseases indicates that transformation by 
EBV is an analogue in vitro of an important pathogenic event 
in vivo (Table I). Infectious mononucleosis is a polyclonal 
disease with a short latency period. When cells are cultured 
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under standard conditions from the peripheral blood of patients 
with infectious mononucleosis, only E BV -transformed cells 
proliferate [3]. Such cells lack chromosomal translocations and 
activated cellular transforming genes and are not tumorigenic 
when inoculated subcutaneously into nu/nu mice [3]. Burkitt's 
lymphoma, however, is monoclonal and has a long latency 
period, minimally 9 months, maximally 48 months. Cells cul­
tured under standard conditions from the tumor mass express 
surface immunoglobulins, generally contain EBV DNA, contain 
changes indicative of tumor progression, and are tumorigenic 
in nu/nu mice [3]. In particular, cells from many Burkitt's 
lymphomas have been shown to contain several specific trans­
locations and an activated transforming gene, B lym [4]. The 
immunoblastic neoplasm associated with EBV may be either 
mono- or polyclonal; it has a short latency period [3]. Prolif­
erating tumor cells have B-cell characteristics and contain EBV 
DNA. The disease occurs, however, only in severely immuno­
compromised hosts. In these three diseases, B cells are infected 
by E pstein- Barr virus. They proliferate in vivo and after cul­
tivation in vitro, although in vitro cultivation has been tested 
infrequently. In the patient with infectious mononucleosis, 
these proliferating B cells are eventually controlled or elimi­
nated, presumably by the competent immune system. In the 
patient with an immunoblastic neoplasm, the proliferating 
EBV -infected cells cannot be eliminated and progress to kill 
the host. In an individual destined to develop Burkitt's lym­
phoma, we hypothesize that the B cells infected by EBV are 
competent to proliferate and are presumably held in check by 
an immune response. In time, a clone of these cells accumulates 
enough variations or progressive cellular changes such that it 
now escapes whatever mechanisms normally would hold it in 
check and grows progressively as a tumor. The preceding con­
siderations are obviously simplistic, but they underscore the 
one phenotype we know EBV contributes to the infected cell: 
the capacity to proliferate. 
TRANSFORMING FUNCTIONS ASCRIBED TO 
EPSTE IN-BARR VIRUS 
What functions must EBV provide for it to induce and 
maintain cell proliferation? These functions can be outlined as 
in Table II. They must include those necessary to induce blast 
formation, those necessary to maintain cell replication, those 
necessary to maintain the viral DNA within the infected cell, 
and finally, those necessary to regulate viral gene expression. 
Much circumstantial evidence can be evinced to indicate that 
EBV must provide these functions in order to transform the 
human B-Iymphocytes into permanently dividing lympho­
blasts. That blast formation and permanent cell replication 
should be considered as two separate functions is best supported 
by recent work studying uninfected human B-Iymphocytes in 
culture [5]. When these cells are exposed to antibodies directed 
against surface IgM, some are induced to form blasts [5]. They 
do not undergo many rounds of replication, however. Appar­
ently, they expose on their surface receptors for one or more 
products that are collectively called B-cell growth factors. The 
addition of B-cell growth factor to the cells previously treated 
with anti-IgM now permits replication of these cells [5]. Infec­
tion by Epstein- Barr virus of B-lymphocytes accomplishes both 
these tasks. Whether or not the virus provides one or more 
gene products to induce these events is not known. 
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TABLE I. Characteristics of lymplwid diseases associated with Epstein�Barr virus· 
------------- --------------------------
Disease 
Infectious mononu­
cleosis 
Burkitt's lymphoma 
lmmunoblastic neo­
plasms associated 
with severe immu­
nodeficiencies 
• See text for references. 
Latency period 
3-4 weeks 
9-48 months 
Several months 
Cells 
infected 
with 
EBV 
B-cell blast 
B-cell blast 
B-cell blast 
TABLE II. Transforming functions a.�cribed to Epstein�Barr virus 
1. Induction of blast formation in the transformed cells 
2. Continued cell proliferation 
3. Maintenance of viral DNA in the transformed cells 
4. Regulation of viral gene expression 
In the infected cell the viral information is generally main� 
tained as a full-length plasmid molecule [1]; that is, the viral 
DNA is not often found to be integrated into the chromosomal 
DNA of the infected cells. The mechanisms by which the viral 
information is maintained in these cells are not now known. It 
seems likely that the virus must provide some functions in cis 
and perhaps some functions in trans in order to maintain its 
DNA information within the infected dividing cell. The term 
cis denotes nondiffusible functions such as a DNA sequence, 
while trans denotes diffusible functions such as a protein or an 
RNA molecule. This virus-host relationship contrasts with that 
of SV 40 in mouse cells in culture or adenoviruses in primary 
rat cells in culture in which the viral information is maintained 
as an integrated entity within the host chromosomal DNA and 
is thus passed to daughter cells passively. 
The fourth function that can be assigned to EBV in trans­
formed cells is that of regulating its own expression. Most cells 
transformed by EBV do not release infectious virus. As with 
other DNA viruses, when an infected cell permits maturation 
of that virus, the cell is destined to die. The fact that EBV­
transformed cells are immortalized indicates that most of these 
cells do not permit maturation of the virus. However, when a 
transformed population of cells is cloned and each clone is 
tested for its capacity to permit maturation and release of 
transforming virus, most clonal populations are found to permit 
these events in a few cells per cell cycle. In 30 clones tested, at 
least 20 permitted the release of virus such that more than 1 in 
106 cells per 24 hours released virus detected in a transforma­
tion assay [6]. This finding indicates that the virus and, pre­
sumably, the cell provide functions that regulate viral expres­
sion such that infrequently any cell will permit the maturation 
of the Epstein-Barr viral genome within it. How these functions 
act is also not known. 
MODELS FOR THE MECHANISM OF 
TRANSFORMATION BY E PSTEIN-BARR VIRUS 
The functions ascribed to EBV in its transformation of 
human B-lymphocytes suggest at least two quite different 
models for the mechanism of transformation by this virus. The 
first model is one in which EBV induces a responsive blast­
state and/or the expression of receptors on the transformed 
cell such that it is now affected by stimulatory signals from the 
outside. The second model is one in which the virus encodes 
products that act internally such that the transformed cell no 
longer requires peculiar external signals to maintain its prolif­
erative state. For example, in the latter model, viral-encoded 
products that act to regulate the maintenance of the viral 
plasmid within the transformed cell might act in trans to 
Chromosomal 
translocations 
and activated EBV-infected 
cellular cells proliferate 
transforming 
genes 
Not detected In vivo and in vitro 
Usually detected In vivo and in vitro 
? In vivo (and in vitro?) 
initiate replication of host chromosomal DNA. Such products 
synthesized constitutively would serve to maintain the cell in 
a permanently replicating state. 
Each of these models deserves further consideration. The 
receptor-induction model has three requirements. First, EBV­
infected cells must be induced to form blasts. Second, if the 
un infected cells do not express the appropriate receptors, the 
infected cells must do so. New receptors could be identified 
among surface antigens newly expressed on transformed cells. 
EBV-transformed cells do express antigens not found on pri­
mary human B-Iymphocytes. These antigens have been desig­
nated Epstein-Barr virus cell surface (EB VCS) antigens [7] and 
B-last 1 antigens [8]. The antigens are candidates for being 
new cell surface receptors induced by EBV. 
Propagating EBV-transformed cells in the presence of high 
concentrations of five monoclonal antibodies directed against 
EBVCS antigens does not affect the growth of these cells (our 
unpublished results). The third facet required in this model is 
a source of stimulatory factors. The newly identified B-cell 
growth factor is apparently not found in fetal calf serum and 
therefore cannot be a factor permitting replication of EBV­
transformed cells in vitro. The stimulatory factors hypothesized 
in this model must be present in the serum in which E BV­
transformed cells are propagated in vitro. Such factors might 
be normal components of serum, or they might be synthesized 
by the infected cells themselves. This latter alternative would 
be analogous to the synthesis of transforming growth factors 
observed in many kinds of tumor cells [9]. There is now no 
evidence that either substantiates or refutes this receptor­
induction model for transformation by EBV. The recent find­
ings that permit the propagation of uninfected human B­
lymphoblasts in culture may permit thoughtful probing of the 
model [5]. 
The second proposed model has two requirements. First, as 
with the receptor-induction model, EBV -infected cells must be 
induced to form blasts. Second, the proliferative state of the 
cell would be maintained by viral products, some or all of which 
would be necessary to maintain the viral DNA within the cell. 
One simple version of this model proposes that viral genes that 
serve to initiate and regulate viral DNA synthesis in a trans­
formed cell also contribute to the initiation and regulation of 
host-chromosomal DNA synthesis. The applications of recom­
binant DNA techniques to the study of Epstein-Barr virus 
should now permit a rigorous testing of the second model. 
ANALYSIS OF TRANSFORMATION BY EPSTEIN­
BARR VIRUS 
Inactivation Experiments 
It is not known how EBV transforms B-lymphocytes. In 
order to gain some insight into the possible mechanisms of 
transformation, a series of indirect experiments measuring how 
much information EBV contributes to transformation has been 
done. In these experiments, the target size for the functions 
needed to transform human B-lymphocytes was measured with 
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a frame-shift mutagen as an inactivating agent [10]. The target 
size for transforming functions of EBV was then compared 
with the target size for plaque formation by herpes simplex 
type 1 (HSV-l), which was measured with the same protocol. 
Making the assumption that most or all of the viral DNA in 
HSV -1 is necessary to form a plaque, one could then calculate 
the amount of DNA within the EBV genome necessary for it 
to transform lymphocytes. These experiments are indirect, but 
they indicate that a large amount of the viral genome, on the 
order of 20-25%, is necessary in order to transform human B­
lymphocytes [10]. This estimate is at least ten times as large 
as the transforming region of any other known transforming 
virus. The findings do not support any particular model for 
transformation by EBV. They do indicate that EBV devotes 
much of its information to transformation. This indication is 
perhaps not surprising given that EBV normally infects and 
transforms lymphocytes during its life cycle in vivo. 
One difficulty in considering these inactivation experiments 
is that their results do not accord entirely with studies of the 
extent of transcription of the EBV genome in transformed cells 
[11,12]. At least four regions of EBV DNA are transcribed in 
the transformed cells. Although their extent adds up to close 
to 20% of the genome (see Fig 1), the largest transcript comes 
from a repetitious element within EBV DNA [11,12]. It is likely 
that an inactivation experiment with a frame-shift mutagen 
would score this genetic region as the size of a single element. 
The amount of viral gene expression detected in the trans­
formed cell therefore seems to be considerably less than that 
predicted to be necessary for transformation by the inactivation 
studies. This contradiction indicates either that the inactiva­
tion studies have severely overestimated the amount of infor­
mation required to transform cells or that some viral informa­
tion necessary for transformation is expressed only early after 
infection. Viral information expressed only early after infection 
might be that postulated in both models to be necessary to 
induce the blast state. 
Inactivation studies of transformation by Epstein -Barr virus 
provided a second result. When gamma rays were used as an 
activating agent, the target size for transformation by EBV was 
found to be as large as the entire genome [10,1:3]. Further 
studies showed that a single double-strand break introduced 
into the viral genome was sufficient to inactivate its capacity 
to transform cells. This result was interpreted to mean that the 
integrity of the viral DNA was necessary either to permit its 
circularization in the transformed cells in order to maintain 
the viral DNA as a plasmid or to permit transcription across 
the newly joined ends of the viral DNA molecule [10]. This 
interpretation is based on the assumption that the viral DNA, 
at least soon after transformation, is maintained as a plasmid. 
This assumption has not been tested directly; when cells that 
have been transformed and propagated for long periods of time 
are studied, however, the bulk of the viral DNA has been found 
to be present as a plasmid molecule. The results of inactivation 
studies using gamma rays and the subsequent interpretation of 
them have led to the conclusion that it is unlikely that the 
kinds of experimental approaches used to define the transform­
ing regions of other DNA viruses, notably the papova and 
adenoviruses, should work with Epstein-Barr virus. With the 
papova and adenoviruses, subgenomic fragments of DNA were 
introduced into recipient cells, and those regions which would 
confer the transformed state on the recipient cells were defined. 
The apparent need to maintain the integrity of the viral DNA 
mitigated against this approach with Epstein-Barr virus. 
Origins of Replication 
In order to define the regions of EBV DNA that are necessary 
for transformation, we have decided first to define those regions 
which are necessary to maintain the plasmid DNA. Combina­
tion of these DNA regions onto one plasmid molecule would 
yield an EBV minireplicon. Once having accomplished this end, 
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it can be determined whether or not the information in the 
minireplicon is sufficient to maintain cell division in a mitogen­
stimulated blast. If the defined viral information were insuffi­
cient to maintain cell division, then genes required to maintain 
cell proliferation could be identified by adding more EBV DNA 
regions to the minireplicon and introducing this larger con­
struct into stimulated blasts. 
The first step in locating those viral DNA regions necessary 
to maintain the viral DNA as a plasmid in transformed cells is 
to locate a viral origin of DNA replication. A viral DNA origin 
is a sequence at which DNA synthesis initiates. One approach 
to identifying such a sequence would be to introduce it into 
cells that already have EBV DNA molecules as plasm ids and 
determine whether the added sequence could replicate employ­
ing the same trans-acting functions that the complete viral 
DNA plasmids do. This we have done. 
To make this approach practicable, two problems had to be 
overcome. Both an efficient means of introducing DNAs into 
cells carrying EBV plasmids had to be found and a method to 
select those cells which have the added DNAs had to be devel­
oped. EBV -transformed lymphoblastoid cells serve poorly as 
recipients for DNAs introduced by calcium-mediated transfec­
tion (our unpublished observations). Exogenous DNAs can be 
introduced into these cells by microinjection with iontophoresis 
such that 20 to 40 percent of the injected cells can express an 
antigen encoded by a specific papova viral DNA (our unpub­
lished observations). Only a few hundred cells could reasonably 
be injected iontophoretically in a single experiment, however, 
so this method was of limited use. It could detect only origins 
of replication that were expressed efficiently and maintained 
while the successfully injected cells were amplified to numbers 
large enough to work with (20 to 30 cell divisions). A solution 
to the problem of introducing DNAs efficiently into cells car­
rying EBV DNA is to use somatic cell hybrids, generated by 
fusing EBV -positive lymphoblasts with adherent cells, as recip­
ients for calcium-mediated transfection. The cell hybrids D98/ 
Raji and D98/HR1 both carry nonintegrated EBV genomes 
and are efficient recipients for transfected DNAs 
[14]. 
The second problem of selecting those cells which had re­
ceived the added DNAs can be solved by ligating to each 
fragment of EBV DNA a recombinant DNA that encodes 
resistance to a derivative of kanamycin, termed G418, that is 
toxic to many mammalian cells. Only those cells which take up 
the added DNAs and express the resistance they encode will 
survive in the presence of G418. 
Fragments of EBV virion DNA were molecularly cloned into 
a recombinant vector, pkan 2, which replicates in E. coli, confers 
resistance to ampicillin in E. coli, confers resistance to G418 in 
mammalian cells, and lacks the "poison" sequence identified 
by Lusky and Botchan [2,15]. The fragments were generated 
by completely cleaving virion DNA with the site-specific en­
donuclease ClaI, HindIII, or Sal! or by cleaving it partially with 
BamBI. Eleven recombinant constructs span the EBV genome 
(Fig 1). They overlap each other at all but two sites (5 and 92 
kbp from the left end) (Fig 1). These molecular clones and two 
others derived from the large internal repetition (Fig 1) were 
introduced into EBV DNA-positive (D98/Raji and D98/HR1) 
or EBV DNA-negative (143 and Balb/c 3T3) cell lines by 
calcium-mediated transfection, and the transfected cells were 
then propagated in G418. Surviving colonies were scored 14 to 
21 days after transfection. One transfected molecular clone 
gave 10- to 100-fold more resistant colonies per microgram of 
added DNA when the EBV DNA-positive cell lines were used 
as recipients than did all other molecular clones tested [16]. 
That clone, pBamC, carries DNA between 5 and 14 kbp from 
the left end (Fig 1) and is a candidate for carrying an EBV 
origin of replication. 
There are several explanations for why one fragment of DNA 
when cloned into pkan 2 and transfected into cells might yield 
an abnormally high number of colonies resistant to G418. The 
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FIG 1. The top line denotes regions of EBV DNA that have been found to be transcribed in transformed cells relative to the endonuclease 
maps of virion DNA depicted below it [11,12]. The vertical lines at the ends of the endonuclease maps denote tandem copies of the terminal 
repeat. The horizontal lines in the center are the map positions and names of the viral DNA fragments inserted into our cloning vehicle, pkan 
2. Endonuclease sites that join inserted DNA to pkan 2 are indicated by B, BamHI; C, ClaI; H, HindIII; and S, Sail. Plasmid names signify the 
cloned endonuclease fragments of EBV. W2 and W' designate two or four tandem copies of the major internal repeat, BamH1 W. pSal-Bam ends 
contain the joined terminals of intracellular EBV DNA. The construction of the plasmids shown here was performed by standard procedures 
[21]. pkan 2 was constructed by replacing the SV40 origin of pSVod [22] with the 31 bp EcoRI to HindIII fragment of pBR322, then by inserting 
between Nael sites at pBR322 positions 403 and 770 the PuuII fragment of HSV-1 containing the thymidine kinase gene [23], and finally 
inserting between the BglII and SmaI sites of the HSV sequences the BglII to SmaI fragment of Tn5 that encodes drug resistance [24]. Except 
when described below, plasmid clones were constructed with EBV virion DNA cleaved partially or completely with the appropriate enzyme. 
Phage EB 45-54 [25] partially cleaved with HindIII was used to construct pHindLHI. To construct pBamZRSal F, the Sail F fragment was 
inserted into pBamZR between the Sail sites in BamHI R and in pkan 2. To construct pBamW2YHFSaIG, pHindB was partially digested with 
Sail to delete from the right end of the Sail G to Sail site in pkan 2. Into the remaining HindIII site of the resulting plasmid we inserted the 
HindIII fragment of pBamWzy that extends from the vector HindIII site through two copies of BamHI W to the HindIII site in BamHI Y. We 
reconstructed the insert of pSal-Bam ends using a pkan 2 clone pBamA, a plasmid clone of EcoRI D from intracellular circular DNA [26] and 
the phage clone EB 0-8 [25]. 
fragment might carry a signal that enhances expression of the 
vector's gene for resistance to G418. It might increase the 
efficiency of maintaining the recombinant DNA in the cell by 
promoting its insertion into the recipient cell's DNA. [It is 
known that the maintenance and continued expression of 
transfected DNAs is usually less efficient (often a 10- to 100-
fold decrease) than is their transient expression alone.] Finally, 
the fragment might increase the yield of resistant colonies if it 
served as an origin of replication permitting the entire recom­
binant molecule to be maintained as a plasmid. This last 
explanation describes why some regions of yeast chromosomal 
DNA, when assayed similarly on plasmids selectable in yeast, 
yield an abnormally high number of surviving colonies [17]. 
Such results have not yet been observed in mammalian recipi­
ent cells, though. 
Two tests were used to determine whether pBamC replicated 
in EBV DNA-positive recipient cells. pBamC was introduced 
into a dam+ strain of E. coli, amplified by propagating the 
bacteria, and isolated. This strain of bacteria methylates the 
adenines with the DNA sequence recognized by the site-specific 
endonucleases Bell and Mbol [18]. Neither enzyme cleaves 
DNAs in which the adenines are methylated within their rec­
ognition sequence. The methylated pBamC was transfected 
into D98/Raji cells and either 3 X 102 or 3 x 10:1 G418-resistant 
colonies were pooled and propagated for approximately 15-20 
population doublings. Small DNAs were isolated from the two 
pools of cells and in separate experiments digested with Bell 
and Mba!. The isolated pBamC, as assayed by the method of 
Southern [19], was digested completely by both enzymes, in­
dicating that it was no longer methylated within those sites 
recognized by the two enzymes ([16] and unpublished obser­
vations). The only obvious mechanism by which pBamC could 
have lost its methyl groups is by its having replicated within 
the G418-resistant cells. It was found that the isolated and 
digested pBamC yielded the same fragments as did pBamC 
propagated in dam- E. coli and similarly digested. This finding 
indicates that authentic pBamC replicates in an EBV DNA­
positive cell line. 
The second assay to determine whether pBamC contains an 
origin of replication was to measure whether there was a net 
increase of pBamC as the transfected G418 cells were propa­
gated. Cultures of 106 D98/Raji cells were exposed to 2.5 Ilg or 
approximately lOll molecules of pBamC. A total of 3 X 10" 
resistant colonies survived selection, and three clones were 
isolated and propagated for approximately 40 population dou­
blings. Small DNAs were isolated, separated electrophoreti­
cally, transferred to nitrocellulose, and detected by nucleic acid 
hybridization. In each case, pBamC was detected at a frequency 
indicating that on average each G418-resistant mammalian cell 
contained more than one plasmid copy of G418 (Table III). 
This finding proves that pBamC replicates as a plasmid in 
EBV DNA-positive cells. In the cited experiments, the net mass 
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TABLE III. Maintenance of pBamC as a pla.�mid in selected D981Raji 
cells upon propagation 
Clone 
A 
A 
B 
B 
C 
C 
Generation 
number at 
sampling" 
12-13 
38-40 
7-8 
38--40 
1 2-13 
38-40 
Average number 
of 
plasmids 
per cell" 
5-20 
20-100 
5-20 
20-100 
5-20 
20-100 
a The generation number was calculated from the number of times 
the cloned cells were passaged multiplied by the reciprocal of the 
dilution at each passage. It was assumed that all cells were viable and 
all were recovered at each passage. 
b The average number of plasmids per cell was measured by isolating 
small DNAs from the cell and detecting them specifically using radio­
actively labeled pkan 2 and the method of Southern [19). A set of 
reconstructions using known amounts of pBamC or pkan 2 was in­
cluded in each Southern transfer to permit quantification of the plas ­
mids isolated from the G418-resistant cells. 
of the transfected DNA increased minimally 10� times (Table 
III). 
No fragment of EBV DNA when molecularly cloned into 
pkan 2 and transfected into the E BV DNA-negative cell lines 
143 and Balb/c 3T3 was found to behave as an origin of 
replication. All the recombinant clones diagramed in Fig 1 were 
tested, and all gave approximately the same low number of 
G418-resistant colonies [16]. A pool of G418-resistant Balb/c 
3T3 colonies initially transfected with pBamC was propagated 
for 15-20 population doublings, and small DNAs were isolated 
from it. No plasmids homologous to pBamC were detected 
among these DNAs. However, DNA homologous to pBamC did 
appear to be integrated into the resistant cells' DNA, thus 
accounting for the survival of the colonies in the presence of 
G418 [16]. 
pBamC contains an origin of DNA replication that functions 
in two EBV DNA-positive cell lines and fails to do so in two 
EBV DNA-negative cell lines [16]. This finding indicates that 
this viral origin may require virally encoded products to work. 
A similar requirement has long been established for the origin 
of replication of the papovavirus SV 40. The large-T antigen of 
SV40 is a viral-encoded protein necessary for that origin [20]. 
It is also possible that this EBV origin of replication functions 
only in certain differentiated cell types, e.g., human B-Iympho­
blasts and human nasopharyngeal epithelial cells. The failure 
of pBamC to replicate in the EBV DNA-negative 143 and Balbi 
c 3T3 cells would then be a result of these cell types not 
expressing the specific differentiated products necessary for the 
pBamC origin to work. 
Future Experiments 
We have identified a region of EBV DNA that acts as an 
origin of replication and found circumstantial evidence for this 
origin's functional requirement for EBV -specific gene products. 
Two experiments must be completed before this new informa­
tion can be used in the study of transformation by E BV. The 
minimal DNA sequence that acts as an origin of replication 
must be delineated, and the possible requirements for viral gene 
products for that origin to function must be established or 
refuted. 
Delineating the viral DNA sequences that constitute this 
origin of replication will be carried out by the surgical methods 
provided by recombining and manipulating DNAs in vitro. 
Deletions within the EBV DNA fragment in pBamC will be 
made by use of various endonucleases and the exonuclease 
Bal31. These smaller viral fragments will be recloned into pkan 
2 and tested for their ability to replicate in E BV DNA-positive 
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cells. This approach has already been used to confine the origin 
within 1800 bp or approximately 1 % of the viral DNA. This 
region previously has had no known function. 
Viral products needed for pBamC or a subfragment of it to 
act as an origin will be searched for by adding other fragments 
of EBV DNA to pBamC and testing for the replication of the 
new construct as a plasmid in EBV DNA-negative cell lines. 
The first fragments to be tested are those shown to encode 
RNA transcripts found in transformed cells (Fig 1). 
With the completion of these two experiments, the infor­
mation necessary for a minimal EBV replicon to act in a 
lymphoblast should be defined. Can it maintain cell division in 
a human B-Iymphoblast? This question will be answered by 
microinjecting the minimal EBV replicon into B-Iymphoblasts 
stimulated with mitogens or immobilized anti-immunoglobulin 
antibodies. If the answer is no, then the question will be asked 
again for minimal replicons to which other regions of EBV 
DNA have been added until the answer is yes. 
Elucidating what viral DNA sequences maintain cell division 
in a stimulated B-Iymphoblast will be one step in analyzing 
transformation by EBV. 
We thank Noreen Warren for her important contributions to this 
work. 
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